瀋陽化工(000698.SZ)一季度預虧1億-1.3億元
格隆匯4月13日丨瀋陽化工(000698.SZ)公佈,預計2022年第一季度歸屬於上市公司股東的淨虧損1億元-1.3億元,上年同期為盈利31299萬元;扣除非經常性損益後的淨虧損1.05億元-1.35億元,上年同期為盈利30935萬元。
2022年一季度,公司主要產品糊狀聚氯乙烯樹脂受下游市場需求萎縮影響,銷售價格及銷量較上年同期降低,導致收入減少,同時,受原料價格上漲影響,造成成本增加;公司子公司瀋陽石蠟化工有限公司受主要生產裝置停車影響,產銷量同比減少,形成虧損;公司子公司山東藍星東大有限公司聚醚多元醇產品銷售價格較上年同期降低。綜上,公司預計2022年一季度經營業績同比虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.